Literature DB >> 9798072

Anticipatory saccades during smooth pursuit eye movements and familial transmission of schizophrenia.

R G Ross1, A Olincy, J G Harris, A Radant, L E Adler, R Freedman.   

Abstract

BACKGROUND: Smooth pursuit eye movement (SPEM) abnormalities are a putative marker of genetic risk for schizophrenia. Accurate SPEM performance requires the subject to activate neural systems responsible for smooth pursuit tracking, while simultaneously suppressing activity of neurons responsible for saccadic movements that would move the eye ahead of the target. This study examined whether specific aspects of SPEM dysfunction cosegregate with genetic risk in parents of schizophrenic probands.
METHODS: Eighteen probands and their parents had SPEM recorded. Parents with an ancestral history of schizophrenia were hypothesized to be more likely than their spouses without such a history to carry a genetic risk for schizophrenia.
RESULTS: Ten families had a single parent with a positive ancestral history for schizophrenia. The frequency of anticipatory saccades, which were mostly small, and the fraction of total eye movement that they represented were the only measures that differentiated the more likely genetic carrier parents in these families from their spouses and age-matched normals.
CONCLUSIONS: Failure to suppress saccadic anticipation of target motion during smooth pursuit appears an aspect of SPEM dysfunction related to presumed genetic risk for schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9798072     DOI: 10.1016/s0006-3223(98)00052-3

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  11 in total

1.  Monitoring eye movements during fMRI tasks with echo planar images.

Authors:  Jason R Tregellas; Jody L Tanabe; David E Miller; Robert Freedman
Journal:  Hum Brain Mapp       Date:  2002-12       Impact factor: 5.038

Review 2.  Endophenotypes in schizophrenia: a selective review.

Authors:  Allyssa J Allen; Mélina E Griss; Bradley S Folley; Keith A Hawkins; Godfrey D Pearlson
Journal:  Schizophr Res       Date:  2009-02-15       Impact factor: 4.939

3.  SPEM dysfunction and general schizotypy as measured by the SSQ: a controlled study.

Authors:  Dirk van Kampen; Jan Berend Deijen
Journal:  BMC Neurol       Date:  2009-06-29       Impact factor: 2.474

4.  Preattentional and attentional cognitive deficits as targets for treating schizophrenia.

Authors:  David L Braff; Gregory A Light
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

5.  Effects of ketamine on brain function during smooth pursuit eye movements.

Authors:  M Steffens; B Becker; C Neumann; A M Kasparbauer; I Meyhöfer; B Weber; M A Mehta; R Hurlemann; U Ettinger
Journal:  Hum Brain Mapp       Date:  2016-11       Impact factor: 5.038

6.  Visual form perception: a comparison of individuals at high risk for psychosis, recent onset schizophrenia and chronic schizophrenia.

Authors:  D Kimhy; C Corcoran; J M Harkavy-Friedman; B Ritzler; D C Javitt; D Malaspina
Journal:  Schizophr Res       Date:  2007-09-19       Impact factor: 4.939

7.  Eye movement dysfunction in first-degree relatives of patients with schizophrenia: a meta-analytic evaluation of candidate endophenotypes.

Authors:  Monica E Calkins; William G Iacono; Deniz S Ones
Journal:  Brain Cogn       Date:  2008-10-18       Impact factor: 2.310

8.  Smoking, Genetics and Schizophrenia: Evidence for Self Medication.

Authors:  Sherry Leonard; Sharon Mexal; Robert Freedman
Journal:  J Dual Diagn       Date:  2007-11-01

9.  Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers.

Authors:  Sharon Mexal; Ralph Berger; Judy Logel; Randal G Ross; Robert Freedman; Sherry Leonard
Journal:  J Mol Neurosci       Date:  2009-08-13       Impact factor: 3.444

10.  Psychosis in children: diagnosis and treatment.

Authors:  H Courvoisie; M J Labellarte; M A Riddle
Journal:  Dialogues Clin Neurosci       Date:  2001-06       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.